Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death

Cell death resistance is a key feature of tumor cells. One of the main anticancer therapies is increasing the susceptibility of cells to death. Cancer cells have developed a capability of tumor immune escape. Hence, restoring the immunogenicity of cancer cells can be suggested as an effective approa...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 12; no. 4; p. 1047
Main Authors Asadzadeh, Zahra, Safarzadeh, Elham, Safaei, Sahar, Baradaran, Ali, Mohammadi, Ali, Hajiasgharzadeh, Khalil, Derakhshani, Afshin, Argentiero, Antonella, Silvestris, Nicola, Baradaran, Behzad
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 23.04.2020
MDPI
Subjects
Adenosine triphosphate
Antigens
Antitumor agents
Apoptosis
Autophagy
Cancer
Cancer therapies
Cell death
Cytokines
Cytotoxicity
Homeostasis
Immune system
Immunogenicity
Immunology
Lymphocytes
Morphology
Mutation
Physiology
Regulation
Review
Tumor cells
Tumors
combination therapy
immunogenic cell death
DAMPs
Online AccessGet full text

Cover

More Information
Summary:Cell death resistance is a key feature of tumor cells. One of the main anticancer therapies is increasing the susceptibility of cells to death. Cancer cells have developed a capability of tumor immune escape. Hence, restoring the immunogenicity of cancer cells can be suggested as an effective approach against cancer. Accumulating evidence proposes that several anticancer agents provoke the release of danger-associated molecular patterns (DAMPs) that are determinants of immunogenicity and stimulate immunogenic cell death (ICD). It has been suggested that ICD inducers are two different types according to their various activities. Here, we review the well-characterized DAMPs and focus on the different types of ICD inducers and recent combination therapies that can augment the immunogenicity of cancer cells.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
The first two authors contributed equally to this work.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12041047